Source comparison
Thymosin Alpha-1 for Hepatitis: Dosing Comparison
Clinical protocols for thymosin alpha-1 in hepatitis vary by indication, co-therapy, and treatment history. The table below summarizes dosing regimens from published trials and current research practices. Chronic HBV (treatment-naive, HBeAg-positive) 1.6mg sub
This comparison does not assign a generated winner or score.
- Clinical protocols for thymosin alpha-1 in hepatitis vary by indication, co-therapy, and treatment history. The table below summarizes dosing regimens from published trials and current research practices.
- Chronic HBV (treatment-naive, HBeAg-positive)
- 1.6mg subcutaneous
- Twice weekly (e.g., Monday/Thursday)
- 24–52 weeks
- Nucleoside analogue (entecavir, tenofovir)
- Combination therapy increases HBeAg seroconversion by 10–15 percentage points vs monotherapy; most trials use 48-week protocols
- Chronic HBV (low-level viremia, persistent HBsAg)
- Twice weekly
- 48–96 weeks
- Nucleoside analogue continuation
- Extended therapy (≥48 weeks) required for HBsAg decline; shorter courses show minimal effect on surface antigen clearance
- Chronic HCV (interferon era, genotype 1)
- 24–48 weeks
- Pegylated interferon-alpha + ribavirin
- Historical regimen. Largely replaced by DAAs; SVR improvement of 12–18% observed in meta-analyses
- Post-SVR HCV (residual fibrosis/inflammation)
- 24 weeks
- None (post-DAA viral clearance)
- Emerging indication; pilot data show liver stiffness reduction and immune function restoration after viral eradication
- HBV-related cirrhosis (compensated)
- 48 weeks minimum
- Nucleoside analogue + beta-blocker if portal hypertension
- Long-term safety demonstrated; immune modulation may reduce HCC risk but requires multi-year follow-up data
- Dosing consistency is critical. Subcutaneous administration delivers more stable plasma levels than intramuscular injection, with peak serum concentration at 2–4 hours and half-life of approximately 2 hours in circulation. Though biological effects on T-cell populations persist 72–96 hours. Twice-weekly dosing maintains continuous immune modulation without daily injections. Peptides sourced from Real Peptides undergo lyophilization and reconstitution with bacteriostatic water; storage at 2–8°C post-reconstitution maintains stability for 28 days, critical for outpatient research protocols.